

Glenmark launches nasal spray in India for treating allergic rhinitis

03 May 2021 | News

Glenmark becomes the first company in the world to launch Ryaltris®-AZ as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg



Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, announced the launch of Ryaltris®-AZ Nasal Spray for the treatment of moderate to severe allergic rhinitis, in India. Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India.

This will provide patients a far more convenient, cost effective treatment option in the country.

Mumbai based Glenmark is the first company in the world to launch Ryaltris®-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg.

Ryaltris®-AZ nasal spray, developed by Glenmark, is a novel fixed-dose combination nasal spray of an antihistamine and a steroid, indicated for treatment of symptoms associated with allergic rhinitis (AR) in patients over 12 years of age. It relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.

Alok Malik, Group Vice President & Business Head, India Formulations said “Glenmark has been a pioneer in providing access to the latest treatment options for respiratory disease patients in India. We are glad to introduce our brand Ryaltris®-AZ, which is clinically studied and cutting-edge, at an affordable cost for patients in the country. Respiratory segment is a key area of focus for Glenmark and the launch of this product will enable us to improve access to allergic rhinitis treatment by providing an effective, convenient, world-class and affordable treatment option to patients in India.”